BBNX vs PATH · rev $65.1M vs P/E 19, rev $1.61B
Beta Bionics, Inc. Common Stock (BBNX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Beta Bionics, Inc. Common Stock (BBNX) is a medical devices company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BBNX revenue for 2024-12-31 was $65.1M. Net income was -$54.8M. Revenue was up 442.9% from 2023-12-31 to 2024-12-31. BBNX currently screens at market cap $640.8M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BBNX currently screens at market cap $640.8M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BBNX and PATH stock pages for the full models.
Not investment advice.